{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:00:55Z","timestamp":1771704055115,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.reprotox.2011.05.009","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T01:05:31Z","timestamp":1306112731000},"page":"93-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Safety of infliximab use during pregnancy"],"prefix":"10.1016","volume":"32","author":[{"given":"Nada","family":"Djokanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chagit","family":"Klieger-Grossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pupco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.reprotox.2011.05.009_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1191\/096032700678815765","article-title":"Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNF alpha monoclonal antibody","volume":"19","author":"Treacy","year":"2000","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/10915810802368196","article-title":"Effects of administration of a monoclonal antibody against mouse tumor necrosis factor alpha during pregnancy and lactation on the pre- and postnatal development of the mouse immune system","volume":"27","author":"Martin","year":"2008","journal-title":"Int J Toxicol"},{"issue":"January (1)","key":"10.1016\/j.reprotox.2011.05.009_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ajg.2008.71","article-title":"Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy","volume":"104","author":"Kane","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"10.1016\/j.reprotox.2011.05.009_bib0020","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0897.2007.00499.x","article-title":"Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system","volume":"58","author":"Martin","year":"2007","journal-title":"Am J Reprod Immunol"},{"issue":"12","key":"10.1016\/j.reprotox.2011.05.009_bib0030","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0035","first-page":"A54","article-title":"Safety of infliximab in Crohn's disease: data from 5000 patients TREAT registry","volume":"126","author":"Lichtenstein","year":"2004","journal-title":"Gastroenerology"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0040","unstructured":"Mahadevan U. Pregnancy in IBD. Presented at 22nd International Conference of Organization of Teratology Information Specialist. June 27\u2013July 1, 2009, Rio Grande, Puerto Rico."},{"issue":"6","key":"10.1016\/j.reprotox.2011.05.009_bib0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"January 6","key":"10.1016\/j.reprotox.2011.05.009_bib0050","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.dld.2006.01.017","article-title":"Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease","volume":"38","author":"Tursi","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1440-1746.2003.02983.x","article-title":"Pregnancy and exposure to infliximab (antitumor necrosis factor-alpha monoclonal antibody)","volume":"18","author":"Burt","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0065","first-page":"S349","article-title":"Pregnancy in women receiving anti TNF therapy. Experience in Spain","volume":"52","author":"Joven","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0070","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.22028","article-title":"British Society for Rheumatology Biologics Register. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.reprotox.2011.05.009_bib0075","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ibd.20319","article-title":"Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception","volume":"14","author":"Angelucci","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.reprotox.2011.05.009_bib0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"9","key":"10.1016\/j.reprotox.2011.05.009_bib0085","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kem068","article-title":"Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy","volume":"46","author":"Rosner","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.reprotox.2011.05.009_bib0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery","volume":"43","author":"Kane","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.reprotox.2011.05.009_bib0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000262284","article-title":"Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature","volume":"220","author":"Puig","year":"2010","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.reprotox.2011.05.009_bib0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.reprotox.2011.05.009_bib0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3899\/jrheum.081083","article-title":"Do tumor necrosis factor inhibitors cause malformations in humans?","volume":"36","author":"Koren","year":"2009","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.reprotox.2011.05.009_bib0110","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3899\/jrheum.090141","article-title":"Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?","volume":"36","author":"Winger","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.reprotox.2011.05.009_bib0115","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4 (Suppl. 1)","key":"10.1016\/j.reprotox.2011.05.009_bib0120","first-page":"A144","article-title":"Infliximab levels in infants born to women with inflammatory bowel disease","volume":"132","author":"Mahadevan","year":"2007","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.reprotox.2011.05.009_bib0125","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reprotox.2011.05.009_bib0130","doi-asserted-by":"crossref","first-page":"A-69","DOI":"10.1016\/S0016-5085(08)60323-6","article-title":"The effect of maternal peripartum infliximab use on neonatal immune response","volume":"134","author":"Mahadevan","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.reprotox.2011.05.009_bib0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.reprotox.2011.05.009_bib0140","first-page":"2500","article-title":"Bacillus calmette-gu\u00e9rin vaccination in a patient treated with infliximab","volume":"32","author":"Toussirot","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.reprotox.2011.05.009_bib0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of gastroenterology on biological therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.reprotox.2011.05.009_bib0150","first-page":"33","article-title":"The use of biologic therapy in the pregnant patient","volume":"34","author":"Mahadevan","year":"2010","journal-title":"Pract Gastroenterol"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623811001584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623811001584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:24Z","timestamp":1760189544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623811001584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0890623811001584"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2011.05.009","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of infliximab use during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2011.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}